Laser Light Therapy for Stroke Victims

• Sudden Severe Headache
• Difficulty Swallowing (Dysphagia)
• Loss of Consciousness
• Transient Ischemic Attack (TIA)
• Hemorrhagic Stroke

1,With the ability to pass through the skull, the 810nm wavelength promotes brain recovery following traumatic injury and lessens chronic nerve damage.

2,Patients suffering from severe depression and anxiety can benefit from the therapeutic effects of the 810nm wavelength.

3,Cytochrome C oxidase in mitochondria absorbs NIR light.

4,Improved circulation, elevated energy, protective effects on neurons, and decreased inflammation.

5,Suitable for the treatment of stroke, traumatic brain injuries,

6,High quality with much more affordable pricing.

7,Simple to use, appropriate for either home or clinic applications.

8,Includes complimentary treatment protocols.

9,Excellent customer support after purchase.

10. Brain Segmentation: 12 regions, each with customizable power, frequency, and duration.

11. Nasal and Ear Applicators: Controlled by remote, improving treatment effectiveness.

Enhancing Mitochondrial Function: Increases ATP production, providing energy for cellular repair and regeneration.

Reducing Oxidative Stress: Boosts antioxidant enzyme activity, minimizing cellular damage.

Promoting Neuroprotection and Neurogenesis: Protects neurons from damage, reduces inflammation, and supports the growth of new neurons.

Improving Cerebral Blood Flow: Enhances blood circulation and oxygenation, ensuring brain tissues receive adequate nutrients.

Alternative Treatment for Stroke with Low-Level Laser Therapy (LLLT)

Low-level laser therapy (LLLT) has been studied as an alternative approach for treating stroke, demonstrating neuroprotective properties and regulating several biological processes. Light from LLLT can penetrate various tissues, including the scalp and skull, reaching the brain. Numerous clinical and preclinical studies have shown that this method can enhance stroke recovery. In these studies, strokes were induced in rat and rabbit models, revealing that transcranial LLLT (tLLLT) applied within 24 hours of stroke onset could yield significant beneficial effects. For rat models, strokes were caused by permanent occlusion of the middle cerebral artery using a filament inserted into the carotid artery or through craniotomy. In rabbit models, strokes were induced using the small clot embolic model by injecting a microclot made from donor rabbit blood.



Clinical Trials of tLLLT in Human Stroke Patients

Several clinical trials have been conducted to evaluate the efficacy of tLLLT in human patients who have suffered an acute stroke. The initial study, NEST-1, involved 120 patients aged 40 to 85 years with ischemic stroke and measurable neurological deficits. This trial aimed to establish the safety and efficacy of laser therapy for stroke within 24 hours. The results showed that transcranial PBM significantly improved outcomes in stroke patients when applied approximately 18 hours post-stroke across the entire head (using 20 points in the 10/20 EEG system) regardless of stroke location. Only one LLLT session was administered, and five days later, there was significantly greater improvement in the Real-LLLT group compared to the Sham group (p < 0.05, NIH Stroke Severity Scale). This significant improvement persisted at 90 days post-stroke, with 70% of patients in the Real-LLLT group achieving a successful outcome, compared to only 51% in the control group.



The subsequent clinical trial, NEST-2, enrolled 660 patients aged 40 to 90 years, who were randomly divided into two groups (331 received LLLT, 327 received sham treatment). The study found beneficial results (p < 0.04) for patients with moderate and moderate-severe strokes, but not for those with severe strokes, who received the Real laser treatment protocol.



Conclusion

These findings highlight the potential of LLLT as a promising treatment for stroke recovery. By penetrating the scalp and skull to reach brain tissues, LLLT offers a non-invasive option that can significantly improve outcomes when administered promptly after a stroke. Continued research and clinical trials will be essential to further establish LLLT as a standard treatment for stroke patients.